<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03876886</url>
  </required_header>
  <id_info>
    <org_study_id>BXu-1839</org_study_id>
    <nct_id>NCT03876886</nct_id>
  </id_info>
  <brief_title>The Trial Comparing Dose-dense AC-T With TP as Adjuvant Therapy for TNBC With Homologous Recombination Repair Deficiency</brief_title>
  <official_title>Randomized Phase Ⅲ Trial Comparing Dose-dense Epirubicin and Cyclophosphamide Followed by Paclitaxel With Paclitaxel Plus Carboplatin as Adjuvant Therapy for Triple-negative Breast Cancer With Homologous Recombination Repair Deficiency</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chinese Academy of Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chinese Academy of Medical Sciences</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this trial is to compare the 3-year disease-free survival of dose-dense&#xD;
      epirubicin and cyclophosphamide followed by paclitaxel with paclitaxel plus carboplatin as&#xD;
      adjuvant therapy for triple-negative breast cancer with homologous recombination repair&#xD;
      deficiency.&#xD;
&#xD;
      The other purpose of this trial is to observe the patient's tolerance.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Triple-negative breast cancer (TNBC) lack the expression of oestrogen receptor (ER),&#xD;
      progesterone receptor(PR) and human epidermal growth factor receptor 2 (HER2) , and&#xD;
      characterizes an aggressive behavior with higher risk of recurrence and death compared to&#xD;
      other breast cancer subtypes. Little therapeutic progress has been made in adjuvant therapy&#xD;
      in TNBC during the past decades and the standard of care is still missing.&#xD;
&#xD;
      Pre-clinical and clinical data suggest that platinum-based regimens represent an emerging&#xD;
      therapeutic option for selected patients with homologous recombination repair deficiency&#xD;
      (HRD). The HR system is critical in regulating and maintaining genome stability, and is one&#xD;
      of the most commonly altered systems in TNBCs, up to 15-20% TNBC patients carry germline&#xD;
      BRCA1/2 mutations. Other HR genes included PALB2, RAD51 etc. Tumors that harbor HRD possess&#xD;
      an increased burden of genomic aberrations and lesions, and have been shown to have increased&#xD;
      sensitivity to DNA crosslinking agents such as platinum salts. Platinum-based regimens have&#xD;
      been encouraging in TNBC patients with HRD, given increases in both pathologic complete&#xD;
      response (pCR) rates in neoadjuvant trials and objective response rates(ORR) in metastatic&#xD;
      diseases. Further information are needed on how platinum-containing therapies affect&#xD;
      long-term outcomes in the adjuvant setting.&#xD;
&#xD;
      In this trial, the investigators intend to compare the 3-year disease-free survival (DFS) of&#xD;
      dose-dense epirubicin and cyclophosphamide followed by paclitaxel with paclitaxel plus&#xD;
      carboplatin as adjuvant therapy in high-risk node-negative or node-positive TNBC patients&#xD;
      with HRD. The other purpose of this trial is to observe the participants' tolerance.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 22, 2019</start_date>
  <completion_date type="Anticipated">December 2024</completion_date>
  <primary_completion_date type="Anticipated">February 2024</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>3-year disease-free survival</measure>
    <time_frame>Three years</time_frame>
    <description>The participants will be followed by the telephone for the duration, an expected average of 3 years.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]</measure>
    <time_frame>Three years</time_frame>
    <description>Incidence of neutropenic fever; Incidence of grade 3-4 side effects; Toxicity assessed by NCI CTCAE v5.0</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Triple Negative Breast Cancer</condition>
  <arm_group>
    <arm_group_label>AC-T(dose-dense)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>A: epirubicin, pharmorubicin (EPI) C: cyclophosphamide (CTX） T: paclitaxel (PTX）</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TP(dose-dense)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>T: paclitaxel (PTX） P: carboplatin (CBP)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Epirubicin</intervention_name>
    <description>Epirubicin 90mg/m2 iv d1 or divide into two days</description>
    <arm_group_label>AC-T(dose-dense)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>cyclophosphamide600mg/m2 iv d1,q14d*4cycles;with G-CSF support: 3ug/kg ih</description>
    <arm_group_label>AC-T(dose-dense)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paclitaxel</intervention_name>
    <description>paclitaxel 175mg/m2 iv d1, q14d*4cycles</description>
    <arm_group_label>AC-T(dose-dense)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carboplatin</intervention_name>
    <description>carboplatin AUC=3 iv d2, q14d*8cycles;with G-CSF support: 3ug/kg ih</description>
    <arm_group_label>TP(dose-dense)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paclitaxel</intervention_name>
    <description>paclitaxel 175mg/m2 iv d1, q14d*8cycles</description>
    <arm_group_label>TP(dose-dense)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. 18-60 years&#xD;
&#xD;
          2. Histologically confirmed adenocarcinoma of the breast, complete tumor removal by&#xD;
             either modified radical mastectomy or local excision plus axillary lymph node&#xD;
             dissection (i.e., breast conservation therapy) or sentinel node biopsy. (Tumor-free&#xD;
             margins at least 1 mm for both invasive and noninvasive carcinoma except for lobular&#xD;
             carcinoma in situ (less than 1 mm allowed);&#xD;
&#xD;
          3. Histologically confirmed ER(-) PR(-) and HER-2(IHC(immunohistochemistry) 0-1+ or FISH&#xD;
             (fluorescence in situ hybridization) negative)&#xD;
&#xD;
          4. Next-generation sequencing confirmed homologous recombination repair deficiency&#xD;
&#xD;
          5. Meet one of the following criteria:&#xD;
&#xD;
        (1) Positive axillary lymph nodes; (2) Negative axillary lymph nodes with at least one of&#xD;
        the following risk factors: age&lt;= 35 years; grade III; infiltrative tumor size &gt; 2cm;&#xD;
        intravascular tumor embolus; Ki-67&gt;=50%.&#xD;
&#xD;
        6. Eastern Cooperative Oncology Group (ECOG) Performance Score 0-1 7. Adequate bone marrow&#xD;
        reserve with ANC &gt; 1500, HGB &gt; 9g/dL and platelets &gt; 100,000.&#xD;
&#xD;
        8. Adequate renal function with serum creatinine &lt; 2.0. 9. Adequate hepatic reserve with&#xD;
        serum bilirubin &lt; 2.0, AST/ALT &lt; 2X the upper limit of normal, and alkaline phosphatase &lt;&#xD;
        5X the upper limit of normal. Serum bilirubin &gt; 2.0 is acceptable in the setting of known&#xD;
        Gilbert's syndrome.&#xD;
&#xD;
        10. Not pregnant, and on appropriate birth control if of child-bearing potential.&#xD;
&#xD;
        11. Written informed consent according to the local ethics committee requirements.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Prior systemic treatment of breast cancer, including chemotherapy;&#xD;
&#xD;
          2. Metastatic breast cancer;&#xD;
&#xD;
          3. Patients with medical conditions that indicate intolerant to adjuvant therapy and&#xD;
             related treatment, including uncontrolled pulmonary disease, diabetes mellitus, severe&#xD;
             infection, active peptic ulcer, coagulation disorder, connective tissue disease or&#xD;
             myelo-suppressive disease;&#xD;
&#xD;
          4. Has active hepatitis B or hepatitis C with abnormal liver function tests (LFTs) or is&#xD;
             known to be HIV positive;&#xD;
&#xD;
          5. Contraindication for using dexamethasone;&#xD;
&#xD;
          6. History of congestive heart failure, uncontrolled or symptomatic angina pectoris,&#xD;
             arrhythmia or myocardial infarction; poorly controlled hypertension (systolic BP&gt;180&#xD;
             mmHg or diastolic BP&gt;100 mmHg);&#xD;
&#xD;
          7. Pregnant or breast feeding.&#xD;
&#xD;
          8. Hepatic, renal, or bone marrow dysfunction as detailed above.&#xD;
&#xD;
          9. Known severe hypersensitivity to any drugs in this study;&#xD;
&#xD;
         10. Treatment with any investigational drugs within 30 days before the beginning of study&#xD;
             treatment.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Binghe Xu</last_name>
    <phone>+86-10-87788120</phone>
    <email>xubinghe@medmail.com.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Qing Li</last_name>
    <phone>+86-10-87788120</phone>
    <email>cheryliqing@hotmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>National Cancer Center, Cancer Hospital/Chinese Academy of Medical Sciences and Peking Union Medical College</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100021</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Binghe XU, M.D.</last_name>
      <phone>86-10-88788826</phone>
      <email>xubinghe@medmail.com.cn</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2019</verification_date>
  <study_first_submitted>March 14, 2019</study_first_submitted>
  <study_first_submitted_qc>March 14, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 15, 2019</study_first_posted>
  <last_update_submitted>March 20, 2019</last_update_submitted>
  <last_update_submitted_qc>March 20, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">March 21, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Chinese Academy of Medical Sciences</investigator_affiliation>
    <investigator_full_name>Binghe Xu</investigator_full_name>
    <investigator_title>Professor of Medical Oncology</investigator_title>
  </responsible_party>
  <keyword>homologous recombination deficiency;adjuvant chemotherapy;anthracycline;taxanes;platinum</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Triple Negative Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Epirubicin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

